Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | GRM5 | P41594 | 2/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | PNMT | P11086 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MMP9 | P14780 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25669814 | 0.86 | CYP3A4 (0.41) | RAD52RECQLCYP3A4TSHRHSD17B10 | |
| SCHEMBL13937972 | 0.72 | PIK3R1 (0.33) | MMP9 | |
| SCHEMBL8369140 | 0.71 | RAD52 (0.45) | RAD52RECQLCYP3A4TSHRHSD17B10 | |
| SCHEMBL6369625 | 0.69 | CYP3A4 (0.53) | RAD52RECQLCYP3A4TSHRHSD17B10 | |
| SCHEMBL19965750 | 0.68 | CYP3A4 (0.51) | RAD52RECQLCYP3A4TSHRHSD17B10 | |
| SCHEMBL18684040 | 0.67 | CYP3A4 (0.46) | RAD52RECQLCYP3A4TSHRHSD17B10 | |
| SCHEMBL15006492 | 0.67 | — | — | |
| SCHEMBL8352174 | 0.66 | — | — | |
| SCHEMBL14925526 | 0.66 | CYP3A4 (0.49) | RAD52RECQLCYP3A4TSHRHSD17B10 | |
| SCHEMBL10035000 | 0.66 | MMP9 (0.38) | GRM5CHRM3HRH3MMP9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210330672-A1 | USE OF BCL6 INHIBITORS FOR TREATING AUTOIMMUNE DISEASES | TEQLA THERAPEUTICS, INC. | 2021-10-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210330672-A1 | USE OF BCL6 INHIBITORS FOR TREATING AUTOIMMUNE DISEASES | BCL6, BCL6B, BCL3 | RAD52 3960/4885RECQL 4458/4885CYP3A4 4831/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.